Published in Vaccine Weekly, July 18th, 2007
David L. Parker, Ph.D, J.D., Introgen's senior vice president of Intellectual Property said, "The issuance of this patent is significant for Introgen in that the development of adenoviral formulations with improved storage stability and ease of shipping and handling is a is sought-after goal by the adenovirus...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.